These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 33144196)

  • 1. Japan's innovation for global health - GHIT's catalytic role.
    Katsuno K
    Parasitol Int; 2021 Feb; 80():102232. PubMed ID: 33144196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Straight talk with...BT Slingsby. Interviewed by Cassandra Willyard.
    Slingsby BT
    Nat Med; 2013 Dec; 19(12):1553. PubMed ID: 24309642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [International Partnership for Therapeutic Drug Development of NTDs by DNDi].
    Yamada H; Hirabayashi F; Brünger C
    Yakugaku Zasshi; 2016; 136(2):213-22. PubMed ID: 26831796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tracking Japan's development assistance for health, 2012-2016.
    Nomura S; Sakamoto H; Sugai MK; Nakamura H; Maruyama-Sakurai K; Lee S; Ishizuka A; Shibuya K
    Global Health; 2020 Apr; 16(1):32. PubMed ID: 32293475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Industry, Academia and Government Partnership through the Global Health Innovative Technology Fund (GHIT)].
    Hinoshita E
    Yakugaku Zasshi; 2016; 136(2):237-42. PubMed ID: 26831799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reconsidering Japan's underperformance in pharmaceuticals: evidence from Japan's anticancer drug sector.
    Umemura M
    Enterp Soc; 2010; 11(3):560-93. PubMed ID: 20821877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Historical sketch of modern pharmaceutical science and technology (Part 4). Post World War II 50 years].
    Yamakawa K
    Yakushigaku Zasshi; 1995; 30(2):75-90. PubMed ID: 11613536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Study of Global Health Strategy Based on International Trends: -Promoting Universal Health Coverage Globally and Ensuring the Sustainability of Japan's Universal Coverage of Health Insurance System: Problems and Proposals.
    Hatanaka T; Eguchi N; Deguchi M; Yazawa M; Ishii M
    Japan Med Assoc J; 2015 Sep; 58(3):78-101. PubMed ID: 26870622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Japan's development cooperation for health in Vietnam: a first holistic assessment on Japan's ODA and non-ODA public resources cooperation.
    Lee S; Ishizuka A; Tachimori H; Uechi M; Akashi H; Hinoshita E; Miyata H; Shibuya K
    BMC Public Health; 2021 Nov; 21(1):2175. PubMed ID: 34837970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Global fund: Analyzing 10 Years of bridging health inequalities.
    Olufadewa II; Adesina MA; Oladele RI; Oladoye MJ; Eke NF
    Int J Health Plann Manage; 2021 Mar; 36(2):282-287. PubMed ID: 33336419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strengthening the Competitiveness of Japan's Pharmaceutical Industry: Analysis of Country Differences in the Origin of New Drugs and Japan's Highly Productive Firm.
    Okuyama R
    Biol Pharm Bull; 2023; 46(5):718-724. PubMed ID: 37121698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tracking the global spread of vaccine sentiments: the global response to Japan's suspension of its HPV vaccine recommendation.
    Larson HJ; Wilson R; Hanley S; Parys A; Paterson P
    Hum Vaccin Immunother; 2014; 10(9):2543-50. PubMed ID: 25483472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Japan's anti-nuclear weapons policy misses its target, even in the war on terrorism.
    DiFilippo A
    Med Confl Surviv; 2003; 19(3):235-48. PubMed ID: 12964707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Japan's Advocacy for Human Security in Global Politics: Case Study of Japan's Grant Assistance for Grass-Roots Human Security Projects (GGP) in the State of Sabah, Malaysia, 2000-2021.
    Dollah R; Peters D; Hassan WSW; Omar MA; Rahim MSA; Jafar A
    East Asia (Piscataway); 2023; 40(2):151-174. PubMed ID: 36788944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new Korean Research Investment for Global Health Technology (RIGHT) Fund to advance innovative neglected-disease technologies.
    Hotez PJ; Bush K; Oswald A; Rockman G; Lim IT; Jee Y; Moon CJ; Kim JH; Kim Y
    PLoS Negl Trop Dis; 2020 Sep; 14(9):e0007956. PubMed ID: 32881862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Re-invigorating Japan's commitment to global health: challenges and opportunities.
    Llano R; Kanamori S; Kunii O; Mori R; Takei T; Sasaki H; Nakamura Y; Kurokawa K; Hai Y; Chen L; Takemi K; Shibuya K
    Lancet; 2011 Oct; 378(9798):1255-64. PubMed ID: 21885096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Perspective on the drug discovery and market landscape in Japan: can it compete in the worldwide arena?
    Kobayashi T
    Expert Opin Drug Discov; 2006 Aug; 1(3):205-9. PubMed ID: 23495842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Corporate Efforts to Research and Develop Therapeutic Agents for Infectious Diseases That Threaten Human].
    Yoshida R; Kaki R; Yoshida O; Shishido T; Kato T; Yamano Y
    Yakugaku Zasshi; 2022; 142(7):691-696. PubMed ID: 35781495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Limited alignment of publicly competitive disease funding with disease burden in Japan.
    Nomura S; Yoneoka D; Tanaka S; Makuuchi R; Sakamoto H; Ishizuka A; Nakamura H; Kubota A; Shibuya K
    PLoS One; 2020; 15(2):e0228542. PubMed ID: 32040510
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.